• Clinical Trials - Melanoma

    Study Objective Contact
    ECOG 1609 : A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon á-2b for Resected High-Risk Melanoma [LCID Study Number: 2011-054] The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on you and your melanoma to find out which is better. In this study, you will get either ipilimumab or the interferon alfa-2b. You will not get both. We plan to determine whether ipilimumab stops or delays your cancer from returning in comparison to interferon alfa-2b. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Amanda M. Pietras,
    Sherry G. Heldt, RN.